Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda I Adler

Showing results (11-20 of 96) with videos related to

Pageof 10
Sort By:
The Lancet. Oncology|August 13, 2017
NICE guidance on cabozantinib for previously treated advanced renal cell carcinomaAhmed Elsada, Amanda I Adler
The Lancet. Gastroenterology & Hepatology|December 3, 2019
NICE guidance on sorafenib for treating advanced hepatocellular carcinomaAmanda I Adler, Frances Sutcliffe
The Lancet. Oncology|April 15, 2019
NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaAhmed Elsada, Amanda I Adler
JAMA|May 25, 2021
Adjusting for Nonadherence or Stopping Treatments in Randomized Clinical TrialsAmanda I Adler, Nicholas R Latimer
Current Atherosclerosis Reports|August 14, 2012
Recent findings on the effects of marine-derived n-3 polyunsaturated fatty acids on urinary albumin excretion and renal functionC Christine Lee, Amanda I Adler
BMJ Medicine|March 20, 2023
Extrapolation beyond the end of trials to estimate long term survival and cost effectivenessNicholas R Latimer, Amanda I Adler
The Lancet. Haematology|April 24, 2021
Accurate accounting of caplacizumab cost effectiveness - Authors' replyMary Hughes, Nicole Elliot, Amanda I Adler
The Lancet. Oncology|January 29, 2017
NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutationBoglarka Mikudina, Melinda Goodall, Amanda I Adler
The Lancet. Oncology|April 11, 2012
NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapyFiona Rinaldi, Elisabeth George, Amanda I Adler
The Lancet. Oncology|July 27, 2012
NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimenAnwar Jilani, Elisabeth George, Amanda I Adler
Pageof 10

Showing results (11-20 of 96) with videos related to

Sort By:
Pageof 10
The Lancet. Oncology|August 13, 2017
NICE guidance on cabozantinib for previously treated advanced renal cell carcinomaAhmed Elsada, Amanda I Adler
The Lancet. Gastroenterology & Hepatology|December 3, 2019
NICE guidance on sorafenib for treating advanced hepatocellular carcinomaAmanda I Adler, Frances Sutcliffe
The Lancet. Oncology|April 15, 2019
NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaAhmed Elsada, Amanda I Adler
JAMA|May 25, 2021
Adjusting for Nonadherence or Stopping Treatments in Randomized Clinical TrialsAmanda I Adler, Nicholas R Latimer
Current Atherosclerosis Reports|August 14, 2012
Recent findings on the effects of marine-derived n-3 polyunsaturated fatty acids on urinary albumin excretion and renal functionC Christine Lee, Amanda I Adler
BMJ Medicine|March 20, 2023
Extrapolation beyond the end of trials to estimate long term survival and cost effectivenessNicholas R Latimer, Amanda I Adler
The Lancet. Haematology|April 24, 2021
Accurate accounting of caplacizumab cost effectiveness - Authors' replyMary Hughes, Nicole Elliot, Amanda I Adler
The Lancet. Oncology|January 29, 2017
NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutationBoglarka Mikudina, Melinda Goodall, Amanda I Adler
The Lancet. Oncology|April 11, 2012
NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapyFiona Rinaldi, Elisabeth George, Amanda I Adler
The Lancet. Oncology|July 27, 2012
NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimenAnwar Jilani, Elisabeth George, Amanda I Adler
Pageof 10